Pablo A. Silveira
YOU?
Author Swipe
View article: Tropoelastin modulates systemic and local tissue responses to enhance wound healing
Tropoelastin modulates systemic and local tissue responses to enhance wound healing Open
Wound healing is facilitated by biomaterials-based grafts and substantially impacted by orchestrated inflammatory responses that are essential to the normal repair process. Tropoelastin (TE) based materials are known to shorten the period …
View article: CD300f signalling induces inhibitory human monocytes/macrophages
CD300f signalling induces inhibitory human monocytes/macrophages Open
The CD300 glycoproteins are a family of related leucocyte surface molecules that regulate the immune response via their paired triggering and inhibitory receptors. Here we studied CD300f, an apoptotic cell receptor, and how it modulates th…
View article: Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis
Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis Open
Antibodies targeting the activation marker CD83 can achieve immune suppression by targeting antigen-presenting mature dendritic cells (DC). This study investigated the immunosuppressive mechanisms of anti-CD83 antibody treatment in mice an…
View article: Dihydrotestosterone (DHT) Enhances Wound Healing of Major Burn Injury by Accelerating Resolution of Inflammation in Mice
Dihydrotestosterone (DHT) Enhances Wound Healing of Major Burn Injury by Accelerating Resolution of Inflammation in Mice Open
Androgens have been known to inhibit cutaneous wound healing in men and male mice. However, in children with major burn injuries, a synthetic androgen was reported clinically to improve wound healing. The aim of this study is to investigat…
View article: Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia
Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia Open
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly reduces the rate of relapse in acute myeloid leukemia (AML) but comes at the cost of significant treatment-related mortality. Despite the reduction in relapse ove…
View article: Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? Open
From monoclonal antibodies (mAbs) to Chimeric Antigen Receptor (CAR) T cells, immunotherapies have enhanced the efficacy of treatments against B cell malignancies. The same has not been true for Acute Myeloid Leukemia (AML). Hematologic to…
View article: Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody Open
Objectives Effective antibody–drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective was to determine C…
View article: Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics
Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics Open
Myeloid lineage cells present in human peripheral blood include dendritic cells (DC) and monocytes. The DC are identified phenotypically as HLA-DR+ cells that lack major cell surface lineage markers for T cells (CD3), B cells (CD19, CD20),…
View article: <scp>CD</scp>300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation
<span>CD</span>300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation Open
Antibody‐based therapy in acute myeloid leukemia ( AML ) has been marred by significant hematologic toxicity due to targeting of both hematopoietic stem and progenitor cells ( HSPC s). Achieving greater success with therapeutic antibodies …
View article: CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential
CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential Open
CD83 is a member of the immunoglobulin (Ig) superfamily and is expressed in membrane bound or soluble forms. Membrane CD83 (mCD83) can be detected on a variety of activated immune cells, although it is most highly and stably expressed by m…
View article: Examination of CD302 as a potential therapeutic target for acute myeloid leukemia
Examination of CD302 as a potential therapeutic target for acute myeloid leukemia Open
Acute myeloid leukemia (AML) is the most common form of adult acute leukemia with ~20,000 new cases yearly. The disease develops in people of all ages, but is more prominent in the elderly, who due to limited treatment options, have poor o…
View article: On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy Open
Monoclonal antibodies targeting co-inhibitory immune checkpoint molecules have been successful in clinical trials of both solid and hematological malignancies as acknowledged by the 2018 Nobel Prize in Medicine, however improving clinical …
View article: Bone Marrow Graft-Versus-Host Disease in Reduced Intensity Conditioned Major Histocompatibility Complex Matched Murine Allogeneic Hematopoietic Cell Transplantation
Bone Marrow Graft-Versus-Host Disease in Reduced Intensity Conditioned Major Histocompatibility Complex Matched Murine Allogeneic Hematopoietic Cell Transplantation Open
Background: The majority of clinical allogeneic haemopoietic cell transplants (alloHCT) are now performed using reduced intensity conditioning (RIC) instead of myeloablative conditioning (MAC). However, the biology underlying RIC treatment…
View article: CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma Open
Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or rel…
View article: Characterization of the Expression and Function of the C-Type Lectin Receptor CD302 in Mice and Humans Reveals a Role in Dendritic Cell Migration
Characterization of the Expression and Function of the C-Type Lectin Receptor CD302 in Mice and Humans Reveals a Role in Dendritic Cell Migration Open
C-type lectin receptors play important roles in immune cell interactions with the environment. We described CD302 as the simplest, single domain, type I C-type lectin receptor and showed it was expressed mainly on the myeloid phagocytes in…
View article: CMRF-56<sup>+</sup>blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses
CMRF-56<sup>+</sup>blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses Open
There are numerous transcriptional, proteomic and functional differences between monocyte-derived dendritic cells (Mo-DC) and primary blood dendritic cells (BDC). The CMRF-56 monoclonal antibody (mAb) recognizes a cell surface marker, whic…
View article: A CD2 high‐expressing stress‐resistant human plasmacytoid dendritic‐cell subset
A CD2 high‐expressing stress‐resistant human plasmacytoid dendritic‐cell subset Open
Human plasmacytoid dendritic cells (pDCs) were considered to be a phenotypically and functionally homogeneous cell population; however, recent analyses indicate potential heterogeneity. This is of major interest, given their importance in …
View article: New insights into the phenotype of human dendritic cell populations
New insights into the phenotype of human dendritic cell populations Open
HLDA10 is the Tenth Human Leukocyte Differentiation Antigen (HLDA) Workshop. The HLDA Workshops provide a mechanism to allocate cluster of differentiation (CD) nomenclature by engaging in interlaboratory studies. As the host laboratory, we…